Nexentis Technologies Inc 近日宣布,其旗下的Mitocarex Bio项目已成功达成一项关键的研发里程碑。该项目在通往临床前开发的道路上取得了重要进展,成功生成了一种经过显著优化的先导化合物分子。这一突破标志着该候选药物在早期开发阶段迈出了坚实的一步。
Nexentis Technologies Inc 近日宣布,其旗下的Mitocarex Bio项目已成功达成一项关键的研发里程碑。该项目在通往临床前开发的道路上取得了重要进展,成功生成了一种经过显著优化的先导化合物分子。这一突破标志着该候选药物在早期开发阶段迈出了坚实的一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.